124340-94-9

Upstream product

• 3218-36-8 4-Phenylbenzaldehyde 
• 603-81-6 2,3-diaminobenzoic acid 
• 606-18-8 3-nitroanthranilic acid 
• 16533-45-2 ethyl 2-carboxy-3-nitrobenzoate 
• 1248541-54-9 2-biphenyl-4-yl-1H-benzoimidazole-4-carboxylic acid methyl ester 

Downstream Products

• 1248541-99-2 2-([1,1'-biphenyl]-4-yl)-1H-benzimidazole-4-carboxamide 
• 124340-66-5 2-Biphenyl-4-yl-1H-benzoimidazole-4-carboxylic acid (2-dimethylamino-ethyl)-amide 

Relevant academic research and scientific papers

DIHYDROOROTATE DEHYDROGENASE INHIBITORS

The invention relates to compounds of formula (I) wherein R1, R2, X1, X2, Y, Ra, Rb, Q have the meanings given in claim 1. The compounds are useful e.g. in the treatment of autoimmune disorders, such as multiple sclerosis and also in the treatment of cancer disorders.

Potential Antitumor Agents. 59. Structure-Activity Relationships for 2-Phenylbenzimidazole-4-carboxamides, a New Class of "Minimal" DNA-Intercalating Agents Which May Not Act via Topoisomerase II

A series of substituted 2-phenylbenzimidazole-4-carboxamides has been synthesized and evaluated for in vitro and in vivo antitumor activity.These compounds represent the logical conclusion to our search for "minimal" DNA-intercalating agents with the lowest possible DNA-binding constants.Such "2-1" tricyclic chromophores, of lower aromaticity than the structurally similar 2-phenylquinolines, have the lowest DNA binding affinity yet seen in the broad series of tricyclic carboxamide intercalating agents.Despite very low in vitro cytotoxicities, several of the compoundshad moderate levels of in vivo antileukemic effects.However, the most interesting aspect of their biological activity was the lack of cross-resistance shown to an amsacrine-resistant P388 cell line, suggesting that these compounds may not express their cytotoxicity via interaction with topoisomerase II.